Per the company's PR this morning, Craig will present nonclinical data on PV-10 at the Society for Immunotherapy of Cancer Annual Meeting on October 26 and 27, 2012 in North Bethesda, Maryland.
I think the presentation could address Provectus' work further elucidating the mechanism of action of the "bystander effect" in mice, expanding this work into other cancers (besides melanoma) and combinational therapies. This immuotherapy-oriented presentation of Craig's of mouse MOA data would follow his similarly themed presentation (but focused on the platform) at MD Becker's 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference in New York on October 4.
Craig will present next week at BioX, an investor-oriented conference in Stamford, Connecticut.
No comments:
Post a Comment